The update adds efficacy and safety data on adults newly diagnosed with pulmonary arterial hypertension.
News|Articles|November 3, 2003
New Product Newswire
New Product Newswire
Advertisement
Advertisement
Related to this article
The approval is the first new treatment advance in more than 30 years for chronic kidney disease for adults with type 1 diabetes.
The approval extends the medication to a younger pediatric population, marking the first FDA-approved treatment for children with this immunodeficiency.
Advertisement
Advertisement
Trending on Drug Topics
1
GLP-1 Therapy Must Prioritize Metabolic Quality Over Weight Loss
2
COVID-19 Vaccine Hesitancy in 2026: How Attitudes Have Shifted
3
High-Dose Vaccines Reduce Hospital Stays in Older Adults With Lung Disease
4
Social Media Best Practices for Pharmacists: Why Visibility Matters
5